Updated on 31 December 2012
Hope for migraine patients – FDA gives nod to Breckenridge Pharma's Rizatriptan Benzoate ANDA
Singapore: US-based Breckenridge Pharmaceutical received approval from the US FDA for the Abbreviated New Drug Application (ANDA) for Rizatriptan Benzoate tablets. The firm is expected to launch the drug immediately.
The tablets are being manufactured and supplied by Natco Pharma, India, and will be available in both 5 mg and 10 mg strengths. Rizatriptan Benzoate tablets are AB rated to Maxalt, a $320 million dollar brand drug marketed by Merck. Maxalt is a prescription medicine indicated for the acute treatment of migraines.
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
